AORT Logo

Artivion, Inc. (AORT) Insider Trading Activity

NYSE$29.51
Market Cap
$1.26B
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
322 of 877
Rank in Industry
39 of 109

AORT Insider Trading Activity

AORT Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$53,141
1
4
Sells
$7,108,568
26
96

Related Transactions

SEMEDO ANTHONY B.director
1
$53,141
1
$242,628
$-189,487
Berry Lance AExecutive VP, CFO
0
$0
2
$210,754
$-210,754
GREEN ANDREW MVP Regulatory
0
$0
1
$228,540
$-228,540
Getz Matthew AVP, Human Resources
0
$0
1
$238,434
$-238,434
Stanton Marshall S.SVP, Clinical & MD Affair
0
$0
3
$475,010
$-475,010
Horton AmyVP, Chief Accounting Officer
0
$0
4
$570,699
$-570,699
Davis John EChief Commercial Officer
0
$0
4
$675,515
$-675,515
Holloway Jean FSVP, General Counsel
0
$0
8
$1.13M
$-1.13M
Mackin James PPresident & CEO
0
$0
2
$3.34M
$-3.34M

About Artivion, Inc.

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Insider Activity of Artivion, Inc.

Over the last 12 months, insiders at Artivion, Inc. have bought $53,141 and sold $7.11M worth of Artivion, Inc. stock.

On average, over the past 5 years, insiders at Artivion, Inc. have bought $260,731 and sold $4.01M worth of stock each year.

Highest buying activity among insiders over the last 12 months: SEMEDO ANTHONY B. (director) — $53,141.

The last purchase of 2,100 shares for transaction amount of $53,141 was made by SEMEDO ANTHONY B. (director) on 2025‑03‑05.

List of Insider Buy and Sell Transactions, Artivion, Inc.

2025-05-09SaleStanton Marshall S.SVP, Clinical & MD Affair
10,548
0.0249%
$29.13
$307,265
+1.05%
2025-03-11SaleDavis John EChief Commercial Officer
15,100
0.0361%
$23.61
$356,549
+2.56%
2025-03-11SaleHolloway Jean FSVP, General Counsel
18,020
0.0431%
$23.61
$425,510
+2.56%
2025-03-06SaleMackin James PPresident & CEO
88,439
0.2108%
$24.77
$2.19M
-2.62%
2025-03-06SaleDavis John EChief Commercial Officer
2,618
0.0062%
$24.80
$64,939
-2.62%
2025-03-06SaleHolloway Jean FSVP, General Counsel
2,124
0.0051%
$24.80
$52,685
-2.62%
2025-03-06SaleBerry Lance AExecutive VP, CFO
4,909
0.0117%
$24.80
$121,764
-2.62%
2025-03-06SaleHorton AmyVP, Chief Accounting Officer
1,048
0.0025%
$24.80
$25,995
-2.62%
2025-03-06SaleStanton Marshall S.SVP, Clinical & MD Affair
1,603
0.0038%
$24.80
$39,761
-2.62%
2025-03-05SaleHolloway Jean FSVP, General Counsel
472
0.0011%
$25.29
$11,935
-5.08%
2025-03-05PurchaseSEMEDO ANTHONY B.director
2,100
0.0049%
$25.30
$53,141
-5.08%
2025-02-24SaleMackin James PPresident & CEO
42,156
0.0972%
$27.31
$1.15M
-13.21%
2025-02-24SaleDavis John EChief Commercial Officer
2,846
0.0066%
$27.31
$77,713
-13.21%
2025-02-24SaleDavis John EChief Commercial Officer
6,457
0.0149%
$27.31
$176,315
-13.21%
2025-02-24SaleHolloway Jean FSVP, General Counsel
3,685
0.0085%
$27.31
$100,623
-13.21%
2025-02-24SaleHolloway Jean FSVP, General Counsel
5,335
0.0123%
$27.31
$145,678
-13.21%
2025-02-24SaleHorton AmyVP, Chief Accounting Officer
3,323
0.0077%
$27.31
$90,738
-13.21%
2025-02-24SaleStanton Marshall S.SVP, Clinical & MD Affair
4,687
0.0108%
$27.31
$127,983
-13.21%
2025-02-24SaleBerry Lance AExecutive VP, CFO
3,259
0.0075%
$27.31
$88,990
-13.21%
2024-12-11SaleHolloway Jean FSVP, General Counsel
8,070
0.0194%
$30.13
$243,109
-6.94%
Total: 251
*Gray background shows transactions not older than one year

Insider Historical Profitability

29.7%
Mackin James PPresident & CEO
860368
2.0148%
$25.39M418
+33.26%
Davis John EChief Commercial Officer
208778
0.4889%
$6.16M220
+28.47%
Holloway Jean FSVP, General Counsel
197184
0.4618%
$5.82M029
Berry Lance AExecutive VP, CFO
153431
0.3593%
$4.53M02
Horton AmyVP, Chief Accounting Officer
146651
0.3434%
$4.33M028
Stanton Marshall S.SVP, Clinical & MD Affair
105332
0.2467%
$3.11M010
SEMEDO ANTHONY B.director
35659
0.0835%
$1.05M21
+9.19%
Getz Matthew AVP, Human Resources
34116
0.0799%
$1.01M09
GREEN ANDREW MVP Regulatory
33503
0.0785%
$988,673.5308
ANDERSON STEVEN GExecutive Chairman
1300676
3.0459%
$38.38M09
LEE DAVID ASHLEYExecutive VP, COO & CFO
347217
0.8131%
$10.25M219
+25.04%
Capps Scott BVP, Clinical Research
148640
0.3481%
$4.39M05
McCall Ronald Ddirector
121768
0.2852%
$3.59M022
FRONK DAVIDVP Reg. Affrs. and Qual Assur.
101528
0.2378%
$3M01
Burris Jeffrey WVice President & Gen. Counsel
93576
0.2191%
$2.76M05
Gale David CVP, Research & Development
77135
0.1806%
$2.28M02
SEERY GERALD BSr. VP, Sales and Marketing
71999
0.1686%
$2.12M01
RONALD C ELKINSdirector
64843
0.1518%
$1.91M021
Benson Jamesdirector
54086
0.1267%
$1.6M05
Maney Rochelle L.VP, Quality
46569
0.1091%
$1.37M08
Maier Dennis BSVP, Operations
34724
0.0813%
$1.02M08
Anderson Bruce G.VP, US Sales &Global Marketing
34564
0.0809%
$1.02M06
Bullock Jamesdirector
34023
0.0797%
$1M10
+47.76%
Tyrs FlorianVP, Global Operations
21558
0.0505%
$636,176.5803
*Gray background shows insiders who have made transactions during last year

AORT Institutional Investors: Active Positions

Increased Positions74+35.58%3M+9.69%
Decreased Positions84-40.38%1M-3.92%
New Positions18New987,505New
Sold Out Positions25Sold Out510,266Sold Out
Total Postitions198-4.81%38M+5.77%

AORT Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Blackrock, Inc.$144,710.0014.43%6.2M-230,390-3.58%2025-03-31
Vanguard Group Inc$65,438.006.52%2.8M+1,771+0.06%2024-12-31
Perceptive Advisors Llc$65,177.006.5%2.79M00%2024-12-31
Macquarie Group Ltd$63,860.006.37%2.74M-8,997-0.33%2024-12-31
Morgan Stanley$55,060.005.49%2.36M-90,519-3.69%2024-12-31
Juniper Investment Company, Llc$48,950.004.88%2.1M00%2024-12-31
Wellington Management Group Llp$38,730.003.86%1.66M+3,817+0.23%2024-12-31
State Street Corp$36,061.003.6%1.55M+30,903+2.04%2024-12-31
Dimensional Fund Advisors Lp$34,358.003.43%1.47M-68,849-4.47%2024-12-31
Gw&K Investment Management, Llc$25,935.002.59%1.11M-23,816-2.1%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.